November 11, 2011
In a matter before the U.S. Supreme Court, Prometheus Laboratories Inc. responded October 31, 2011 to Mayo Clinic's claim that observed correlations between blood test results and patient health are not patent-eligible subject matter. Prometheus' views were supported by nine amicus briefs, including one by Finnegan partner Erika H. Arner and another by Finnegan partner Denise W. DeFranco. “When considering the patent eligibility of medical diagnostic processes, this court should take care not to disrupt patenting of software and other computer technologies,” writes Ms. Arner on behalf of SAP America Inc. and in favor of affirming the Federal Circuit's opinion. Finnegan partner Denise W. DeFranco filed the AIPLA brief, and added an argument in the context of the recently enacted America Invents Act (AIA). Ms. DeFranco wrote, “In the AIA, Congress amended many provisions of the patent statute, but notably Congress declined to amend section 101, even though the process included numerous occasions for it to consider policy issues concerning patentable subject matter.”
Award/Ranking
Finnegan Named Firm of the Year at the 2024 Managing Intellectual Property Americas Awards
April 26, 2024
Commentary
World IP Day: EPO Reveals 33% Jump in Cleantech Inventions Over Five Years
April 26, 2024
Award/Ranking
Finnegan Shortlisted for the 2024 Asian Legal Business Japan Law Awards
April 26, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.